Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies Reports Revenues Of $11.4m
For the year ended June 30, 2009, Palatin Technologies has reported a total revenues of $11.4m, compared to $11.5m for year ended June 30, 2008. Palatin’s net loss
For the year ended June 30, 2009, Palatin Technologies has reported a total revenues of $11.4m, compared to $11.5m for year ended June 30, 2008. Palatin’s net loss
Meda Pharmaceuticals (Meda) has announced the commercial availability of Edluar (zolpidem tartrate sublingual tablets) in the US. Edluar is indicated for the short-term treatment of insomnia. Sharon Clarke,
PriceSpective, a value strategy consultancy that provides pricing and reimbursement services to pharmaceutical and biotechnology companies, has hired two senior experts for its UK office. Walter Colasante, join
OctoPlus has won an expansion of a drug delivery technology evaluation contract with an existing client, a global pharmaceutical company. In 2008 and 2009 OctoPlus performed preliminary feasibility
Opexa Therapeutics (Opexa) has reported results from further analysis of the double-blind, placebo-controlled, 52-week phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS). The
XenoPort has reported preliminary results from a phase 2 clinical trial that evaluated the safety and tolerability of arbaclofen placarbil (AP) (XP19986), when administered without titration to patients
Protalix BioTherapeutics (Protalix) has received notice from the FDA that the FDA’s Office of Orphan Products Development has granted orphan drug designation to prGCD. prGCD is company’s proprietary
GeoPharma has reached agreement with Consolidated Pharmaceutical Group (CPG) and have entered into a Settlement and Mutual Release Agreement and other documents on September 4, 2009, settling all
Repros Therapeutics (Repros) has entered into an agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross
Seattle Genetics has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma. The milestone was triggered by Bayer’s submission of an Investigational New Drug